Targeted covalent-inhibitors (TCIs) have been successfully developed as high-affinity and selective inhibitors of enzymes of the protein kinase family. These drugs typically act by undergoing a Michael addition with an active site cysteine residue, so design of a TCI begins with the identification of a "druggable" cysteine. Thio-Michael additions require the deprotonation of the thiol to form a reactive anionic thiolate, so the acidity of the residue is a critical factor. Experimental measurements of the pKa's of druggable cysteines have not been reported. Here, we report the computed pKa's of druggable cysteines in select protein kinases which are of clinical relevance for targeted therapies. The pKa's of the cysteines are calculated using all-atom replica-exchange thermodynamic integration explicit solvent approach with the CHARMM36 force field. We found that the acidities of druggable cysteines within protein kinases range from 7 to 24 pK units, indicating enormous differences in reactivity. Many of these active-site cysteines have low exposure to solvent molecules, elevating their pKa's. Electrostatic interactions with nearby anionic residues also elevate the pKa's of cysteine residues in the active site. The results suggest that some cysteine residues within kinase binding sites will be slow to react with a TCI due to their low acidity. Several oncogenic kinase mutations were also modeled and were found to have similar pKa's to the wild-type.
The general strategy in kinase inhibitor drug discovery is focused on targeting the ATP-binding pockets of kinase enzymes. Most kinase inhibitors are reversible ATP-competitive inhibitors, which can either bind to the active form of the kinase ("type I" inhibitors), the inactive form ("type II" inhibitors), or an allosteric binding site outside the ATP-binding pocket of the kinase enzyme ("type III & IV" inhibitors). Reversible kinase inhibitors bind to their preferred targets of interest through noncovalent interactions like hydrogen bonding and dispersion interactions. These inhibitors face issues with potency and duration of therapeutic action due to transient inhibition mechanisms and competition with high intracellular ATP concentrations. This can result in decreased in vivo pharmacological activity. Additionally, the structure of the ATP-binding pockets are largely conserved across the kinase family, so some reversible kinase inhibitors may also bind to kinase proteins other than their targets. This raises the potential for crossreactivity and off-target inhibition effects. For example, the multitarget reversible kinase inhibitors sunitinib (sutent) and sorafenib (nexavar) have a wide range of toxic side effects owing to promiscuity in targeting multiple kinase enzymes. 5 Recently, there has been renewed interest among medicinal chemists in developing kinase inhibitors that bind covalently to target proteins. [6] [7] [8] [9] [10] [11] [12] [13] [14] Targeted covalent inhibitors (TCIs) augment conventional noncovalent protein-ligand interactions with a covalent linkage with a side chain of the target. 6, 8 As a result, TCIs can achieve greater binding affinity, a longer residence time, and a pro-longed duration of therapeutic action in comparison to their conventional noncovalent counterparts. Additionally, TCIs can have exceptionally high selectivity for their target kinase because only a small subset of kinases have a reactive amino acid located in a position where a covalent linkage can be formed with the reactive moiety of the bound ligand. 14 The mechanism of covalent kinase inhibition involves the reaction of an electrophilic warhead of the ligand with a nucleophilic amino acid side-chain in the active site of the targeted kinase. Noncatalytic cysteine residues in or near the active sites of protein kinases have been the primary targets of this approach. 15, 16 Cysteine residues possess a chemically-reactive thiol moiety (S-H) that can react with electrophiles. The canonical mechanism for this reaction is a thiol-Michael addition, where the thiol group of the cysteine is deprotonated to form a thiolate. This is illustrated in Scheme 1, where the cysteine thiol is deprotonated to form a thiolate before it reacts with an acrylamide functional group of the inhibitor. 17 Due to the deprotonation step, the rate of covalent modification is dependent on the pKa of the cysteine residue; more reactive cysteines tend to have lower pKa's due to the increased probability of the cysteine being in the thiolate state. Scheme 1. Mechanism of covalent modification of cysteine thiol side-chain by an acrylamide warhead moiety (in red). 1 Several structure-guided bioinformatics studies have identified cysteines within the human kinome that could be targeted by covalent-modifier drugs. 15, [18] [19] [20] In a landmark study, Taunton and coworkers 18 employed a structural bioinformatics approach to design selective covalent inhibitors of ribosomal protein S6 kinases (RSKs), taking advantage of two selectivity filters: a threonine gatekeeper and a non-conserved solvent-exposed cysteine in the glycine-rich loop region of the ATP-binding pocket. The designed inhibitors were potent and selective for RSK1 and RSK2 kinases over other closely related structural kinase paralogs. 18 Subsequently, Gray and coworkers identified approximately 200 kinases within the human kinome that have a cysteine located in or near the ATPbinding pocket, which could be targeted by a covalent modifier. 19, 21 More recently, predictive algorithms, statistical analysis, and computationally-derived properties have been employed to identify which cysteine residues in kinases are optimal targets for a TCI. 20, [22] [23] [24] A recent study by Bourne and coworkers 23 combined a functionsite interaction fingerprint method and density functional theory calculations to explore covalently modifiable cysteines and their positions across the human kinome where crystal structures are available. The positions of accessible covalent-modifiable cysteines were classified into five regions, namely: phosphate-binding loop (P-loop), roof of binding pocket, front pocket, catalytic loop, and DFG-motif ( Figure 1 ). 23 We have used this classification system in our study. While these structural and bioinformatics studies have identified cysteine residues that have appropriate locations for forming a covalent bond with an inhibitor, no study to date has rigorously assessed if these cysteines will react with an inhibitor at a sufficiently fast rate such that the covalent linkage is formed on the necessary timescale. Knowledge of the pKa's of targetable cysteines in kinases would help to define the intrinsic reactivity of a given cysteine towards an electrophilic inhibitor and provide one of the parameters of the pharmacokinetics of these drugs. These data will guide medicinal chemists in designing drugs that specifically inhibit reactive cysteine targets and avoid wasting effort targeting cysteines that are not reactive.
In this letter, we report the pKa's of druggable cysteine targets in kinases that are active or potential targets for covalent inhibition. Important oncogenic mutants are also included. The kinase structures investigated span the family of the human kinome. Cysteines residues within these proteins were chosen based on previous structural analysis studies or where a covalent inhibitor has been reported. Majority of the druggable cysteines considered were primarily positioned in three kinase segments, namely: front pocket, P-loop, and DFG region. The kinase proteins investigated in this study and targeted cysteine residues are collected in Table 1 . The pKa's of the selected cysteine residues were calculated using all-atom replica-exchange thermodynamic integration (RETI) explicit solvent approach with the CHARMM36 force field, which was found to yield reasonably accurate pKa's for cysteine residues in proteins. 25 This method overcomes the intrinsic limitations of structural analysis and static modeling pKa prediction techniques by employing explicit-solvent molecular dynamics to simulate the dynamic structure of the protein. The relative Gibbs energies of the thiol and thiolate states of the cysteine residues of interest are computed, from which the pKa is determined. The full computational details and PDB ID's of the structures used in the simulations are included in the Supporting Information.
The calculated pKa's of the cysteines range from values as low as 7 pK units to as high as 24 pK units ( Figure 2 ). Most of the targeted cysteine residues have pKa's that are elevated above the pKa of cysteine in solution, 8.6. 26 Only the targeted cysteine residues of c-Src, FGFR4, and JNK2 had pKa's lower than the solution cysteine pKa. There was no systematic trend between target cysteine pKa's and their positions in the kinase segment; although cysteines in the catalytic loop of protein kinases c-KIT and PDGFR reported the highest predicted pKa's. This wide range of acidities indicates that the reactivity of targeted cysteine residues can vary greatly across the kinase family. The variation in the cysteine pKa's is due to differences in the environment around the residue. Thiols have limited intermolecular interactions, but the stability of the thiolate state is sensitive to its interactions with water molecules and other ionizable residues in the protein. 27, 28 A solvent-exposed cysteine thiolate is predicted to have a hydration number of 4.4. The hydration of the cysteine thio-late has a dramatic effect on the pKa (Figure 3 ). Buried cysteine residues that are poorly solvated have higher pKa values, while solvent-exposed cysteine residues have lower pKa values. For example, Cys277 and Cys116 in c-Src and JNK2 kinases are predicted to have relatively low pKa's and have high hydration numbers of 6.0 and 5.5, respectively (Table 2) . Conversely, cysteines with low thiolate hydration numbers (i.e., [3] [4] [5] typically have pKa's greater than 11. This effect is particularly strong for Cys788 of c-KIT (Figure 3 (a) ) and Cys814 of PDGFR , which have very low thiolate hydration numbers and extremely high pKa's. Notable exceptions to this trend include Cys477 in FGFR4 and Cys909 in JAK3. Cys477 in FGFR4 is predicted to have modest hydration number of 4.4 but a pKa of only 7.8. Lys644 is near to Cys477, which results in a stabilizing cation-anion interaction with the cysteine thiolate. This results in a relatively low pKa for Cys477 despite being poorly solvated. On the other hand, Cys909 in JAK3 kinase is predicted to have a high hydration number of 5.4, but an elevated pKa of 13. Asp912 is close to Cys909 and destabilizes the cysteine thiolate anion -elevating the cysteine pKa. The observation that the active-site cysteine residues tend to have elevated pKa's is consistent with other reports that the protonation states of active-site residues can be shifted considerably from their solution values, even when these residues are not catalytic. Isom et al., 29 showed that lysine residues engineered into the active sites of staphylococcal nuclease proteins tended to have low pKa's. In that case, the poor hydration of the residues in the active site favored the deprotonated, neutral state of lysine. For cysteine residues, the low solvent exposure favors the neutral thiol form relative to the thiolate form, resulting in an elevated pKa. This suggests that non-catalytic active-site lysine residues will tend be more reactive towards nucleophiles than amines in solution, while non-catalytic active-site cysteines generally tend to be less reactive than cysteines in solution. 14, 30 Paradoxically, the high pKa's of these cysteine resi- Electrostatic interactions within cysteine environment is another contributing factor to the shift in pKa. EGFR and JAK3 kinases are notable examples where the pKa of a cysteine is affected by electrostatic interactions (Figure 4 ). The pKa of Cys797 in EGFR is predicted to be elevated to 11 due to electrostatic repulsion between the cysteine thiolate and the nearby anionic Asp800. Despite having a highly predicted pKa, Cys797 has been successfully targeted by TCI's like afatinib and neratinib. This indicates that a residue with a pKa of 11 can still be targeted by covalent inhibition. Acidic and basic amino acids can couple with each other such that each will be protonated for a fraction of the time at a given pH. This effect is not included in our RETI-pKa calculations, which assume that the protonation of residues other than the cysteine remains constant. To test this assumption, we also calculated the titration curves for select cysteines and aspartates in EGFR and JAK3 kinases simultaneously using constant pH replica-exchange molecular dynamics 32 (pH REMD) in explicit solvent. Details about the method and simulation procedure can be found in the Supporting Information. The percentage of the time the residue is deprotonated as a function of pH is plotted in Figure 5 . Although these methods are fundamentally different approaches for calculating pKa and employ different force fields, the pH REMD titration curve for Cys797 in EGFR and Cys909 in JAK3 agree reasonably well with the RETI-pKa calculations. The equivalence point on the titration curve of Cys797 (Figure 5 (a) ) is evaluated to a pKa value of 13.5. Similarly, the equivalence point of the titration curve of Cys909 is elevated to a pKa value of 13.1 (Figure 5 (b) ). These curves show that these residues inside the enzyme binding site have pKa's that are higher than in solution, 26 but there appears to be no coupling effect between the protonation states of these residues with nearby aspartic acid residues, which is evident in the characteristic sigmoidal shape pH titration curve of both residues ( Figure 5 ). Generally, we expect that an acidic residue near to a cysteine will elevate the pKa of the cysteine without becoming coupled. In summary, we have calculated the pKa's of cysteines residues could be targets for covalent-modifier drugs. The pKa's were computed using rigorous simulation methods with an explicit representation of the solvent. Our analysis suggests that the degree of solvation of the thiolate state and interactions between the thiolate and other amino acids in the binding site are responsible for the perturbation in the pKa's of druggable cysteines in kinases. The general trend is for the pKa's of the cysteines to be elevated because they are 4 poorly solvated in comparison to residues on the surface of the protein. The pKa of a cysteine residue can also be perturbed by electrostatic interactions with other charged residues; nearby anionic residues increase pKa due to electrostatic repulsion with the cysteine thiolate. These simulations indicate that cysteine residues in kinase active sites tend to have widely different susceptibility to reaction with an electrophilic drug due to differences in their acidity. Computational prediction of the stability of the thiolate state and other intermediate states of covalent modification will enable more rational development of this important class of drugs.
